Globally, less than two thirds of children living with HIV who are taking treatment are ‘virally suppressed’, according to new research from UNSW Sydney’s Kirby Institute and the global IeDEA consortium, published today in The Lancet HIV.
Viral suppression for HIV means that treatments are working effectively to protect health and prevent the transmission of HIV to others. UNAIDS has set a target of achieving 95% viral suppression among all people living with HIV on treatment by 2030.
“We estimate viral suppression one, two and three years after people start taking antiviral treatment, so that we can understand how well the treatments are working overtime,” said Professor Matthew Law from the Kirby Institute. “The data among adults on treatment in our studies show that after accounting for people being lost to care, viral suppression was achieved in an estimated 79% of adults at 1 year, and 65% at 3 years. However, viral suppression is poorer among children at an estimated 64% at 1 year and 59% at 3 years.”
Dr Azar Kariminia from the Kirby Institute, who is senior author on the study, says children and adolescents face unique barriers to achieving viral suppression. “It can be challenging for them to take treatment regularly, and children rely on caregivers who are often having to manage their own medical needs. There are also a range of factors that stem from stigma and discrimination, including a fear of disclosing the child’s HIV status.”
This study is part of a major research collaboration called IeDEA, the International epidemiology Databases to Evaluate AIDS, which draws together HIV epidemiological data and expertise across seven regions: North America; the Caribbean and Central and South America; Central, East, Southern and Western Africa; and the Asia-Pacific. The Kirby Institute co-leads IeDEA Asia-Pacific with the Foundation for AIDS Research’s (amfAR) TREAT Asia program. IeDEA is funded by the United States National Institutes of Health.
For this study, the researchers analysed data from 21,594 children/adolescents and 255,662 adults from 148 sites in 31 countries, who initiated treatment between 2010 and 2019.
Dr Annette Sohn, from amfAR’s TREAT Asia program, is Co Principal Investigator for IeDEA Asia-Pacific (along with Professor Matthew Law from the Kirby Institute). She says that “while there has been substantial progress in the global response to HIV, the needs of children and adolescents often fall behind those of adults. Our efforts must extend beyond ensuring access to paediatric medicines to address the social and developmental challenges they face in growing up with HIV if we are to achieve the WHO targets by 2030.”
The need for global scale up of viral load testing
Viral load testing is essential to find out whether HIV treatments are working effectively. It is recommended by WHO at six and 12 months following the initiation of treatment, and then every 12 months thereafter.
While viral load testing is common in high-income countries, scaling up accessible viral load testing in resource-limited settings remains a challenge.
Funded through the Australian Government’s Department of Foreign Affairs and Trade’s Centre for Health Security, the Kirby Institute and the Papua New Guinea Institute of Medical Research (PNGIMR) are partnering with the PNG government and a consortium of partners are implementing a program called ‘ACT-UP PNG’ which will scale up HIV viral load testing in two provinces where HIV rates are very high.
“Our work is ensuring that infants and children are afforded the same access to testing and treatment as other people with HIV,” says Dr Janet Gare from the PNGIMR and a Co-Principal Investigator on ACTUP-PNG.
Rather than providing viral load testing in faraway laboratories, ACT-UP PNG provides same-day molecular point-of-care testing and return of results in HIV clinics.
“This brings HIV viral load testing closer to patients, which currently includes children aged 10 and older, and adolescents,” says Dr Gare. “However, we are also pioneering the implementation of a diagnostic platform that will allow the same access to timely HIV viral load testing and results for infants 6-8 weeks of age, and children up to 9 years, who are currently unable to be included in point-of-care methods.
Scientia Associate Professor Angela Kelly-Hanku, who holds joint appointments with the Kirby Institute and PNGIMR, says that leveraging these technologies will make it easier to test for viral suppression in infants and children.
“We cannot end AIDS without addressing the inequalities that exist between paediatric and adult HIV programs. Projects like ACT-UP make a real difference and bring us closer to achieving the UNAIDS targets.”